<SEC-DOCUMENT>0001171843-19-005662.txt : 20190826
<SEC-HEADER>0001171843-19-005662.hdr.sgml : 20190826
<ACCEPTANCE-DATETIME>20190826172122
ACCESSION NUMBER:		0001171843-19-005662
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190826
FILED AS OF DATE:		20190826
DATE AS OF CHANGE:		20190826

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cronos Group Inc.
		CENTRAL INDEX KEY:			0001656472
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38403
		FILM NUMBER:		191053721

	BUSINESS ADDRESS:	
		STREET 1:		720 KING STREET W
		STREET 2:		SUITE 320
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5V 2T3
		BUSINESS PHONE:		(416) 504-0004

	MAIL ADDRESS:	
		STREET 1:		720 KING STREET W
		STREET 2:		SUITE 320
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5V 2T3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PharmaCan Capital Corp.
		DATE OF NAME CHANGE:	20151021
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_082619.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of August 2019</strong></p><p style="text-align: center;">Commission File Number: <strong>001-38403</strong></p><p style="text-align: center;"><font style="font-size: 24pt;"><font style="font-size: 12pt;"><strong>CRONOS GROUP INC.</strong></font></font><br />(Name of registrant)</p><p><!--720 King Street W., Suite 320--><strong>720 King Street W., Suite 320</strong><br /><strong>Toronto, Ontario</strong><br /><strong>M5V 2T3</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;&#160; ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;X ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;CRONOS GROUP INC.&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: August 26, 2019</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Michael Gorenstein&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Michael Gorenstein</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">President and Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table><hr style="page-break-after: always;" noshade="noshade" /><p> <p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0" class="mce-item-table"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Description of Exhibit</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;"><a href="exh_991.htm">News release dated August 26, 2019 &#8211; &#8220;Cronos Group Inc. CEO, Mike Gorenstein, to Present at Barclays 2019 Global Consumer Staples Conference.&#8221;</a> </font></td></tr></table></p><p /></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Cronos Group Inc. CEO, Mike Gorenstein, to Present at Barclays 2019 Global Consumer Staples Conference</strong></font></p><p style="text-align: center;"><strong></strong></p><p ></p>
 <p align="left">TORONTO, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Cronos Group Inc. (&#8220;<strong>Cronos Group</strong>&#8221; or the &#8220;<strong>Company</strong>&#8221;) (TSX: CRON) (Nasdaq: CRON), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer of Cronos Group, will speak at Barclays Global Consumer Staples Conference at 10:30 a.m. ET in Boston, MA.<br ></p>  <p>The presentation will be available on the Investors section of the Company&#8217;s website at ir.thecronosgroup.com/events-presentations.</p>  <p><strong>About Cronos Group Inc.</strong></p>  <p>Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents.&#160;Cronos Group is committed to building disruptive intellectual&#160;property&#160;by advancing&#160;cannabis research, technology and&#160;product development.&#160;With a passion to&#160;responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio.&#160;Cronos Group&#8217;s portfolio includes PEACE NATURALS&#153;,&#160;a global health and wellness platform,&#160;and&#160;two adult-use brands, COVE&#153; and Spinach&#153;.&#160;To learn more about Cronos Group and its brands, please visit:&#8239;www.thecronosgroup.com;&#160;www.peacenaturals.com; www.covecannabis.ca; www.spinachcannabis.com.</p>  <p><strong>Forward-looking statements</strong></p>  <p>This news release contains &#8220;forward-looking information&#8221; and &#8220;forward-looking statements&#8221; within the meaning of applicable Canadian and U.S. securities laws. All information contained herein that is not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking statements can be identified by words or phrases such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;intend&#8221;, &#8220;potential&#8221;, &#8220;estimate&#8221;, &#8220;believe&#8221; or the negative of these terms, or other similar expressions intended to identify forward-looking statements. Some of the forward-looking statements contained in this press release include the Company&#8217;s intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company&#8217;s current Management&#8217;s Discussion and Analysis and Annual Information Form, both of which have been filed on SEDAR and EDGAR and can be accessed at www.sedar.com&#160;and www.sec.gov/edgar, respectively. The forward-looking information included in this news release is made as of the date of this news release and, except as required by law, Cronos Group disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements.</p>  <p><strong>For further information please contact: </strong><br >Anna Shlimak<br >Investor Relations<br >Tel: (416) 504-0004<br >investor.relations@thecronosgroup.com</p>  <p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
